Show simple item record

dc.contributor.authorCanney, Peter Aen
dc.contributor.authorMoore, Michaelen
dc.contributor.authorWilkinson, Peter Men
dc.contributor.authorJames, Roger Den
dc.date.accessioned2011-03-12T23:54:26Z
dc.date.available2011-03-12T23:54:26Z
dc.date.issued1984-12
dc.identifier.citationOvarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker. 1984, 50 (6):765-9 Br J Canceren
dc.identifier.issn0007-0920
dc.identifier.pmid6208925
dc.identifier.urihttp://hdl.handle.net/10541/124420
dc.description.abstractSerum CA 125, quantified by an immunoradiometric assay employing the monoclonal antibody 0C125 was found to be elevated in 48/58 (83%) of patients with established ovarian cancer. All histological types of carcinoma were antigen positive and there was a positive correlation between the frequency and level of serum CA125 and body burden of tumour. Twenty patients undergoing chemotherapy had serial CA125 estimations following a prospective protocol. Variation in CA125 level reflected disease progression or regression in 21/23 instances. Three of 9 patients tested showed an acute elevation of CA125 in the first week following chemotherapy and this effect predicted a good response to treatment. The natural half-life of CA125 in serum was estimated at approximately 4.8 days, sufficiently short to allow changes in tumour volume to be rapidly reflected by a change in circulating antigen level. Although none of 15 patients with non-Hodgkin lymphoma demonstrated antigen levels outside the normal range, 11/27 patients with non-ovarian adenocarcinoma showed elevated CA125 levels, a specificity of 58% for this latter group. The value of CA125 in the management of ovarian malignancy is discussed.
dc.language.isoenen
dc.subject.meshAntigens, Neoplasm
dc.subject.meshEpitopes
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshOvarian Neoplasms
dc.subject.meshProspective Studies
dc.subject.meshTime Factors
dc.titleOvarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker.en
dc.typeArticleen
dc.contributor.departmentPaterson Laboratories and Radiotherapy Department, CHristie Hospital and Holt Radium Institute, Manchester M20 9BXen
dc.identifier.journalBritish Journal of Canceren
html.description.abstractSerum CA 125, quantified by an immunoradiometric assay employing the monoclonal antibody 0C125 was found to be elevated in 48/58 (83%) of patients with established ovarian cancer. All histological types of carcinoma were antigen positive and there was a positive correlation between the frequency and level of serum CA125 and body burden of tumour. Twenty patients undergoing chemotherapy had serial CA125 estimations following a prospective protocol. Variation in CA125 level reflected disease progression or regression in 21/23 instances. Three of 9 patients tested showed an acute elevation of CA125 in the first week following chemotherapy and this effect predicted a good response to treatment. The natural half-life of CA125 in serum was estimated at approximately 4.8 days, sufficiently short to allow changes in tumour volume to be rapidly reflected by a change in circulating antigen level. Although none of 15 patients with non-Hodgkin lymphoma demonstrated antigen levels outside the normal range, 11/27 patients with non-ovarian adenocarcinoma showed elevated CA125 levels, a specificity of 58% for this latter group. The value of CA125 in the management of ovarian malignancy is discussed.


This item appears in the following Collection(s)

Show simple item record